Bio-Rad Laboratories Inc (BUWA.SG)
| Previous close | 260.60 |
| Open | 261.60 |
| Bid | 259.20 x 0 |
| Ask | 265.30 x 0 |
| Day's range | 260.40 - 261.60 |
| 52-week range | 246.10 - 381.40 |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Bio-Rad Names Anette Engelhardt Executive Vice President and President of Clinical Diagnostics Group
HERCULES, Calif., May 30, 2024--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that Anette Engelhardt will join the company as its new Executive Vice President and President of the Clinical Diagnostics Group, effective June 10, 2024.
- Business Wire
Bio-Rad’s Management to Participate in Fireside Chat During Jefferies Global Healthcare Conference
HERCULES, Calif., May 23, 2024--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that its Chief Executive Officer Norman Schwartz and Chief Financial Officer Roop K. Lakkaraju will participate in a fireside chat event during the Jefferies Global Healthcare Conference on Thursday, June 6, 2024, at 10:30 AM Eastern Time (7:30 AM Pacific Time).
- Business Wire
Bio-Rad Reports First-Quarter 2024 Financial Results
HERCULES, Calif., May 07, 2024--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the first quarter ended March 31, 2024.
